How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Pre-Employment Drug Testing & Health Screening Market
- By Test Type: Urine Drug Testing, Hair Drug Testing, Saliva Drug Testing, Blood Drug Testing, Breath Alcohol Testing
- By Health Screening Type: Physical Examination, Laboratory Testing, Vision and Hearing Tests, Immunization Screening, Psychological Assessment
- By End User: Corporate Employers, Healthcare Providers, Government Agencies, Transportation and Logistics Companies, Construction and Manufacturing Firms
- By Service Mode: On-site Testing, Laboratory-based Testing, Mobile Testing Services, Self-collection Kits
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Urine Drug Testing leads By Test Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 281 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.168 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.176 →
Full report · locked preview
Everything inside the Pre-Employment Drug Testing & Health Screening Market report
A complete, evidence-based study - 11 chapters and 118 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Test Type 5
Health Screening Type 5
End User 5
Service Mode 4
Companies profiled
Quest Diagnostics Incorporated
Labcorp (Laboratory Corporation of America Holdings)
Alere Inc. (now part of Abbott Laboratories)
Bio-Reference Laboratories Inc.
MRO Corporation
Concentra Inc.
CRL (Clinical Reference Laboratory)
Medtox Laboratories Inc.
Omega Laboratories Inc.
US Drug Test Centers
Accu Reference Medical Lab
MediCorp Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Quest Diagnostics Incorporated
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Labcorp (Laboratory Corporation of America Holdings)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Alere Inc. (now part of Abbott Laboratories)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bio-Reference Laboratories Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →MRO Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Concentra Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →CRL (Clinical Reference Laboratory)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Medtox Laboratories Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Omega Laboratories Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →US Drug Test Centers
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Accu Reference Medical Lab
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →MediCorp Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →First Advantage Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Sterling Talent Solutions
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →eScreen
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$3,931M by 2033 · 7.8% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Urine Drug Testing41.2
- Hair Drug Testing17.2
- Saliva Drug Testing20.8
- Blood Drug Testing8.6
- Breath Alcohol Testing12.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$711.2M → $1,310M · 7.9%
Europe$495.7M → $865.5M · 7.2%
Asia Pacific$452.6M → $835.0M · 8.0%
Latin America$280.2M → $465.5M · 6.6%
Middle East and Africa$215.5M → $380.7M · 7.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.762026
7.762027
7.782028
7.782029
7.802030
7.822031
7.822032
7.842033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Quest Diagnostics Incorporated13.5
- Labcorp (Laboratory Corporation of America Holdings)14.9
- Alere Inc. (now part of Abbott Laboratories)11.5
- Bio-Reference Laboratories Inc.13.5
- MRO Corporation7.7
- Concentra Inc.10.9
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Test Type19.9%
Health Screening Type31.0%
End User31.0%
Service Mode18.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.0
- Europe22.4
- Asia Pacific21.7
- Latin America12.1
- Middle East and Africa9.9
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Quest Diagnostics Incorporated | 75 | 77 | 88 | 89 | 95 | 98 | 87 |
| Labcorp (Laboratory Corporation of America Holdings) | 83 | 91 | 71 | 83 | 73 | 86 | 81 |
| Alere Inc. (now part of Abbott Laboratories) | 84 | 73 | 75 | 81 | 66 | 72 | 75 |
| Bio-Reference Laboratories Inc. | 60 | 57 | 64 | 64 | 72 | 70 | 65 |
| MRO Corporation | 62 | 64 | 75 | 52 | 55 | 63 | 62 |
| Concentra Inc. | 69 | 49 | 52 | 60 | 46 | 47 | 54 |
| CRL (Clinical Reference Laboratory) | 57 | 41 | 58 | 59 | 41 | 55 | 52 |
| Medtox Laboratories Inc. | 60 | 49 | 46 | 56 | 58 | 43 | 52 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Quest Diagnostics Incorporated
- Labcorp (Laboratory Corporation of America Holdings)
- Alere Inc. (now part of Abbott Laboratories)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Quest Diagnostics Incorporated | ◐ | ◐ | ◐ | ✓ | ✓ | ✓ |
| Labcorp (Laboratory Corporation of America Holdings) | ✓ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Alere Inc. (now part of Abbott Laboratories) | ✓ | ✓ | ✓ | ◐ | ◐ | ◐ |
| Bio-Reference Laboratories Inc. | − | − | ◐ | ◐ | ✓ | − |
| MRO Corporation | − | ◐ | − | − | − | − |
| Concentra Inc. | ✓ | ◐ | − | − | − | − |
| CRL (Clinical Reference Laboratory) | − | − | ◐ | ◐ | − | − |
| Medtox Laboratories Inc. | − | ◐ | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Quest Diagnostics Incorporated87
2Labcorp (Laboratory Corporation of America Holdings)81
3Alere Inc. (now part of Abbott Laboratories)75
4Bio-Reference Laboratories Inc.65
5MRO Corporation62
6Concentra Inc.54
7CRL (Clinical Reference Laboratory)52
8Medtox Laboratories Inc.52
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Quest Diagnostics IncorporatedLabcorp (Laboratory Corporation of America Holdings)
Challenger1
Strong scale, closing on the leaders.
Alere Inc. (now part of Abbott Laboratories)
Contender2
Focused players with pockets of strength.
Bio-Reference Laboratories Inc.MRO Corporation
Niche3
Specialists in a single segment or region.
Concentra Inc.CRL (Clinical Reference Laboratory)Medtox Laboratories Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Test Type in North America, then scale across Pre-Employment Drug Testing & Health Screening Market — a $402M beachhead inside a $5.51B market.
Beachhead (SOM)$402Mobtainable near-term
Serviceable (SAM)$2.26Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Urine Drug Testing
Best fit — highest urgency & budget in Test Type.
Economic buyer79 fit
Hair Drug Testing
Strong fit — clear ROI and a fast path to value.
End user68 fit
Saliva Drug Testing
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Test Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Health Screening Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel28%
Digital / self-serve22%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Test Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Pre-Employment Drug Testing & Health Screening Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified25%
Evaluation13%
Closed-won7%
$21.7KCAC
$79KLTV
3.6:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Pre-Employment Drug Testing & Health Screening Market is a durable-growth opportunity — $8.41B by 2033, compounding at 6.3%.
TAM · 2025$5.15Btoday
TAM · 2033$8.41Bforecast
CAGR6.3%2027–2033
Cumulative$60.0Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$8.41BTotal addressable market
SAM$3.35BServiceable available market
SOM$652MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.3% CAGR
Demand compounds through 2033, outpacing GDP across Test Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Test Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$8.41BLarge & growingTAM by 2033 at 6.3% CAGR
$3.35BServiceable nowreachable with today’s model
$652MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.56BBear4.1% CAGR
$8.41BBase6.3% CAGR
$10.8BBull8.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Health Screening Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Pre-Employment Drug Testing & Health Screening Market — a $6.81B market by 2033. Plan: grow share from 9.8% to 18.1%.
Market size · 2033$6.81Btotal addressable
Market CAGR11.5%2027–2033
Target share18.1%from 9.8% today
Revenue ambition$1.23Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.8% | 18.1% | At risk |
| Revenue | $671M | $1.23B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 35.9% | 38.9% | Ahead |
| Customer retention | 91.0% | 94.4% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Test Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Health Screening Type capability
A defensible second engine — invest in Health Screening Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Test Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Health Screening Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $177M capacity & capability investment
- Greenlight bolt-on M&A in Health Screening Type
- Authorise North America expansion plan
- Fund R&D program for Test Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeBehind
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Pre-Employment Drug Testing & Health Screening Market conversation — a $6.02B market you can size, segment and defend in minutes.
Market size · 2033$6.02Btotal opportunity
Growth4.7%CAGR to 2033
Addressable buyers1,642+accounts in scope
Typical ROI5.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Test Type
Goal Grow share in Test Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.4×return on cost, year one
< 3 mopayback period
$84K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Quest Diagnostics IncorporatedLabcorp (Laboratory Corporation of America Holdings)Alere Inc. (now part of Abbott Laboratories)Bio-Reference Laboratories Inc.MRO CorporationConcentra Inc.CRL (Clinical Reference Laboratory)Medtox Laboratories Inc.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Pre-Employment Drug Testing & Health Screening Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Pre-Employment Drug Testing & Health Screening Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Preeclampsia Therapeutic Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportPreeclampsia Laboratory Testing Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportPreeclampsia Drugs Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportPreeclampsia Diagnostics Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportPrednisone Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportPrednisone Acetate Tablets Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportPrednisolone Transdermal Gel Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportPrednisolone API Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportPrednisolone Acetate API Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportPredisposition Biomarkers Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportPredicure Units Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportPredicure Chair Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.